Targeting Immunotherapy to the Tumor Microenvironment

Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy

(2017) Paul M. Tyler et al.   MOLECULAR CANCER THERAPEUTICS

Improved antitumor activity of TRAIL fusion protein via formation of self-assembling nanoparticle

(2017) Kaizong Huang et al.   Scientific Reports

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors

(2016) Aung Naing et al.   JOURNAL OF CLINICAL ONCOLOGY

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

(2016) I. Tirosh et al.   SCIENCE

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

(2015) Anne Bertrand et al.   BMC Medicine

Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2

(2015) Eric F. Zhu et al.   CANCER CELL

The use of combinations of monoclonal antibodies in clinical oncology

(2015) Linda M. Henricks et al.   CANCER TREATMENT REVIEWS

Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy

(2015) Michael S. Goldberg   CELL

The IL-15-Based ALT-803 Complex Enhances Fc RIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas

(2015) M. Rosario et al.   CLINICAL CANCER RESEARCH

Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer

(2015) Kevin C. Conlon et al.   JOURNAL OF CLINICAL ONCOLOGY

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution

(2015) Alice Tzeng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer

(2015) A. J. Gunderson et al.   Cancer Discovery

Melanoma Induces, and Adenosine Suppresses, CXCR3-Cognate Chemokine Production and T-cell Infiltration of Lungs Bearing Metastatic-like Disease

(2015) E. Clancy-Thompson et al.   Cancer Immunology Research

Regramming myeloid responses to improve cancer immunotherapy

(2015) Yu Zhu et al.   OncoImmunology

C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer

(2015) Moritz Rapp et al.   OncoImmunology

CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models

(2014) Y. Zhu et al.   CANCER RESEARCH

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

(2014) Gregory T Motz et al.   NATURE MEDICINE

Genetic Engineering of Hematopoiesis for Targeted IFN-  Delivery Inhibits Breast Cancer Progression

(2014) G. Escobar et al.   Science Translational Medicine

Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis

(2013) D. E. Sanford et al.   CLINICAL CANCER RESEARCH

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

(2013) Yannick Bulliard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

(2013) M. J. Selby et al.   Cancer Immunology Research

Tumor-Penetrating Peptides

(2013) Tambet Teesalu et al.   Frontiers in Oncology

Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses

(2012) J. B. Mitchem et al.   CANCER RESEARCH

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunomodulatory cytokines as therapeutic agents for melanoma

(2011) Courtney Nicholas et al.   Immunotherapy

IAP inhibitors enhance co-stimulation to promote tumor immunity

(2010) Michael Dougan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor   subunit CD25

(2010) S. Letourneau et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors

(2009) Kazuki N. Sugahara et al.   CANCER CELL

Immune Therapy for Cancer

(2008) Michael Dougan et al.   Annual Review of Immunology

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

(2008) F. S. Hodi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA